Polyrizon Ltd. (PLRZ)

$1.55 -0.09 (-5.49%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 1,429,814
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is he...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 374 0120
Address:
5 HaPnina Street, Ra'anana, Israel
Tbirdyguy
Tbirdyguy Sep. 9 at 5:30 PM
$PLRZ is this going back to 9s?
1 · Reply
MavrickPete
MavrickPete Sep. 7 at 8:27 PM
$PLRZ Tiny market cap: roughly $21–27M, so successful clinical results could have a large percentage impact...
0 · Reply
patrick1956
patrick1956 Sep. 4 at 5:56 PM
$PLRZ .....so the borrowing drop from 150k to...40k at 79%. They still owe 750k back to loan . Volume for selling has drop...to 35k.from over 100k plus...very bullish as their plan to get shares was unsuccessful....even with the 4 million shares offering to 1 institutions.
0 · Reply
focafoca99
focafoca99 Sep. 4 at 5:22 PM
$PLRZ raised $4.0 million in a registered direct offering and concurrent private placement.
1 · Reply
Tbirdyguy
Tbirdyguy Sep. 4 at 4:27 PM
$PLRZ guess im holding past labor day. Can't wait to see what week 18 of "getting ready to start maybe possibly thinking of starting a trial" brings
0 · Reply
patrick1956
patrick1956 Sep. 3 at 4:52 PM
$PLRZ ...before you judged the company...look at who invested the 4 million..end of conversation..very bullish.
1 · Reply
Tbirdyguy
Tbirdyguy Sep. 3 at 4:06 PM
$PLRZ At December 31, 2025, Polyrizon reported approximately $17.5 million of cash and bank deposits and told investors it believed existing resources could fund operations through March 2030. Its 2025 operating cash burn was only about $4.5 million. They either lied or they have fucked up so bad that they desperately needed 4 million cash to stay afloat. Piece of shit company
0 · Reply
patrick1956
patrick1956 Sep. 3 at 3:22 PM
$PLRZ.... 150k shares borrowed at 81%...with shares shorted and dark pool.. ..not enough sellers to cover...let the games continue...meager 4 million offerings is nothing in compared with potential reward.
1 · Reply
OpenOutcrier
OpenOutcrier Sep. 3 at 1:17 PM
$PLRZ (-9.9% pre) Polyrizon launches $4M registered direct offering and private placement https://ooc.bz/l/113212
0 · Reply
focafoca99
focafoca99 Sep. 3 at 1:02 PM
$PLRZ priced a $4.0M registered direct offering and concurrent private placement.
0 · Reply
Latest News on PLRZ
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

Sep 4, 2026, 11:58 AM EDT - 9 days ago

Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

Polyrizon announces $4.0M registered direct offering

2026-09-03T12:55:56.000Z - 10 days ago

Polyrizon announces $4.0M registered direct offering

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

Sep 3, 2026, 8:50 AM EDT - 10 days ago

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

Polyrizon completes all five U.S. site contracts for Nasarix allergy study

2026-09-02T13:16:00.000Z - 11 days ago

Polyrizon completes all five U.S. site contracts for Nasarix allergy study

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

Sep 2, 2026, 7:32 AM EDT - 11 days ago

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

Polyrizon completes clinical site network for NASARIX study

2026-08-20T13:35:29.000Z - 24 days ago

Polyrizon completes clinical site network for NASARIX study

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

Aug 20, 2026, 9:30 AM EDT - 24 days ago

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

Polyrizon announces results from Nasarix biocompatibility evaluation program

2026-07-02T11:40:09.000Z - 2 months ago

Polyrizon announces results from Nasarix biocompatibility evaluation program

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Jul 2, 2026, 7:32 AM EDT - 2 months ago

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Polyrizon receives central IRB approval for Nasarix

2026-06-29T13:15:15.000Z - 2 months ago

Polyrizon receives central IRB approval for Nasarix

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

Jun 29, 2026, 8:44 AM EDT - 2 months ago

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

Polyrizon gets patent for Trap & Target mucoadhesive polymer technology platform

2026-06-17T13:22:01.000Z - 2 months ago

Polyrizon gets patent for Trap & Target mucoadhesive polymer technology platform

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Jun 17, 2026, 8:15 AM EDT - 2 months ago

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

Jun 15, 2026, 8:05 AM EDT - 3 months ago

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

Polyrizon receives notice of European patent publication

2026-06-10T11:50:59.000Z - 3 months ago

Polyrizon receives notice of European patent publication

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

Jun 10, 2026, 7:47 AM EDT - 3 months ago

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

Polyrizon signs agreements with two additional clinical sites for Nasarix study

2026-06-08T13:37:19.000Z - 3 months ago

Polyrizon signs agreements with two additional clinical sites for Nasarix study

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial

Jun 8, 2026, 9:25 AM EDT - 3 months ago

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial

Polyrizon signs clinical trial agreement with clinical research site for Nasarix

2026-05-13T13:54:28.000Z - 4 months ago

Polyrizon signs clinical trial agreement with clinical research site for Nasarix

Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial

May 13, 2026, 9:25 AM EDT - 4 months ago

Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial

Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection

May 11, 2026, 7:25 AM EDT - 4 months ago

Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection

Polyrizon amends patent application claims for intranasal drug delivery platform

2026-05-04T13:47:12.000Z - 4 months ago

Polyrizon amends patent application claims for intranasal drug delivery platform

Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform

May 4, 2026, 8:45 AM EDT - 4 months ago

Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform

Polyrizon Ltd trading halted, volatility trading pause

2026-04-28T14:31:03.000Z - 4 months ago

Polyrizon Ltd trading halted, volatility trading pause

Polyrizon Ltd trading resumes

2026-04-28T14:25:09.000Z - 4 months ago

Polyrizon Ltd trading resumes

Polyrizon files European patent application for Trap & Target platform

2026-04-27T13:57:32.000Z - 4 months ago

Polyrizon files European patent application for Trap & Target platform

Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform

Apr 27, 2026, 9:28 AM EDT - 4 months ago

Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform

Polyrizon files to sell 0.5M shares of common stock for holders

2026-04-23T23:30:28.000Z - 4 months ago

Polyrizon files to sell 0.5M shares of common stock for holders

Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

Apr 8, 2026, 4:16 PM EDT - 5 months ago

Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

Polyrizon Provides 2025 and Recent Highlights

Mar 26, 2026, 9:23 AM EDT - 5 months ago

Polyrizon Provides 2025 and Recent Highlights

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Mar 25, 2026, 5:25 PM EDT - 5 months ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Polyrizon to acquire 20% stake in Colugo for up to $6M

2026-03-24T13:05:32.000Z - 5 months ago

Polyrizon to acquire 20% stake in Colugo for up to $6M

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

Mar 24, 2026, 8:47 AM EDT - 5 months ago

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

Biotech Alert: Searches spiking for these stocks today

2026-03-17T15:51:34.000Z - 6 months ago

Biotech Alert: Searches spiking for these stocks today

Polyrizon signs agreement with research organization for clinical development

2026-03-17T12:35:48.000Z - 6 months ago

Polyrizon signs agreement with research organization for clinical development

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Mar 17, 2026, 8:25 AM EDT - 6 months ago

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Polyrizon announces production of GMP batch of Clinical Trial Material

2026-03-10T12:09:52.000Z - 6 months ago

Polyrizon announces production of GMP batch of Clinical Trial Material

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Mar 10, 2026, 7:55 AM EDT - 6 months ago

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Polyrizon announces results from study evaluating profile of naloxone formula

2026-02-26T13:40:23.000Z - 6 months ago

Polyrizon announces results from study evaluating profile of naloxone formula

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Feb 26, 2026, 8:12 AM EST - 6 months ago

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Feb 17, 2026, 11:32 AM EST - 6 months ago

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

Feb 10, 2026, 6:55 AM EST - 7 months ago

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

Feb 6, 2026, 7:55 AM EST - 7 months ago

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

Feb 4, 2026, 7:12 AM EST - 7 months ago

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Jan 22, 2026, 9:25 AM EST - 7 months ago

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Jan 13, 2026, 8:39 AM EST - 8 months ago

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Jan 8, 2026, 8:45 AM EST - 8 months ago

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

Jan 5, 2026, 9:07 AM EST - 8 months ago

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Jan 2, 2026, 8:30 AM EST - 8 months ago

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Dec 29, 2025, 7:20 AM EST - 8 months ago

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Dec 19, 2025, 8:20 AM EST - 8 months ago

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Dec 11, 2025, 8:15 AM EST - 9 months ago

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

Dec 8, 2025, 8:55 AM EST - 9 months ago

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Dec 4, 2025, 7:32 AM EST - 9 months ago

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Dec 3, 2025, 9:28 AM EST - 9 months ago

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Dec 2, 2025, 7:55 AM EST - 9 months ago

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Nov 6, 2025, 8:55 AM EST - 10 months ago

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Oct 6, 2025, 8:21 AM EDT - 11 months ago

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Sep 19, 2025, 8:15 AM EDT - 11 months ago

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Sep 12, 2025, 7:26 AM EDT - 1 year ago

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Aug 14, 2025, 8:14 AM EDT - 1 year ago

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Jul 15, 2025, 7:55 AM EDT - 1 year ago

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Jun 12, 2025, 7:32 AM EDT - 1 year ago

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Polyrizon Announces Receipt of Nasdaq Delisting Notice

May 23, 2025, 4:15 PM EDT - 1 year ago

Polyrizon Announces Receipt of Nasdaq Delisting Notice

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

May 21, 2025, 7:10 AM EDT - 1 year ago

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

May 13, 2025, 7:45 AM EDT - 1 year ago

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Apr 25, 2025, 7:37 AM EDT - 1 year ago

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Apr 11, 2025, 4:15 PM EDT - 1 year ago

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Apr 2, 2025, 9:05 AM EDT - 1 year ago

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Tbirdyguy
Tbirdyguy Sep. 9 at 5:30 PM
$PLRZ is this going back to 9s?
1 · Reply
MavrickPete
MavrickPete Sep. 7 at 8:27 PM
$PLRZ Tiny market cap: roughly $21–27M, so successful clinical results could have a large percentage impact...
0 · Reply
patrick1956
patrick1956 Sep. 4 at 5:56 PM
$PLRZ .....so the borrowing drop from 150k to...40k at 79%. They still owe 750k back to loan . Volume for selling has drop...to 35k.from over 100k plus...very bullish as their plan to get shares was unsuccessful....even with the 4 million shares offering to 1 institutions.
0 · Reply
focafoca99
focafoca99 Sep. 4 at 5:22 PM
$PLRZ raised $4.0 million in a registered direct offering and concurrent private placement.
1 · Reply
Tbirdyguy
Tbirdyguy Sep. 4 at 4:27 PM
$PLRZ guess im holding past labor day. Can't wait to see what week 18 of "getting ready to start maybe possibly thinking of starting a trial" brings
0 · Reply
patrick1956
patrick1956 Sep. 3 at 4:52 PM
$PLRZ ...before you judged the company...look at who invested the 4 million..end of conversation..very bullish.
1 · Reply
Tbirdyguy
Tbirdyguy Sep. 3 at 4:06 PM
$PLRZ At December 31, 2025, Polyrizon reported approximately $17.5 million of cash and bank deposits and told investors it believed existing resources could fund operations through March 2030. Its 2025 operating cash burn was only about $4.5 million. They either lied or they have fucked up so bad that they desperately needed 4 million cash to stay afloat. Piece of shit company
0 · Reply
patrick1956
patrick1956 Sep. 3 at 3:22 PM
$PLRZ.... 150k shares borrowed at 81%...with shares shorted and dark pool.. ..not enough sellers to cover...let the games continue...meager 4 million offerings is nothing in compared with potential reward.
1 · Reply
OpenOutcrier
OpenOutcrier Sep. 3 at 1:17 PM
$PLRZ (-9.9% pre) Polyrizon launches $4M registered direct offering and private placement https://ooc.bz/l/113212
0 · Reply
focafoca99
focafoca99 Sep. 3 at 1:02 PM
$PLRZ priced a $4.0M registered direct offering and concurrent private placement.
0 · Reply
Schizoo
Schizoo Sep. 2 at 5:26 PM
$PLRZ BALLS N PATIENCE PEOPLE
1 · Reply
Schizoo
Schizoo Sep. 2 at 5:26 PM
$PLRZ hold..
0 · Reply
patrick1956
patrick1956 Sep. 2 at 4:24 PM
$PLRZ ...keep buying these borrowed and dark pool shares...just a matter of time...hedge fund MM..to deep to stop now...imo
1 · Reply
BioTuesdays
BioTuesdays Sep. 2 at 3:15 PM
$PLRZ has completed contracting with the fourth and fifth U.S. clinical sites participating in its study of NASARIX Allergy Blocker (PL-14), moving the program into study execution. https://biotuesdays.com/2026/09/02/polyrizon-completes-site-contracts-for-nasarix-first-in-human-allergy-study/
0 · Reply
patrick1956
patrick1956 Sep. 2 at 2:32 PM
$PLRZ ...Term company shorted and dark pool..was referring to the wall street hedge fund.
0 · Reply
patrick1956
patrick1956 Sep. 2 at 1:57 PM
$PLRZ ...stockwits is not posting my post...they seem to be working with company....company shorted and darkpool 1.575 million shares already outstanding...borrowed 150k shsres at 77%..according to finwit..today.
1 · Reply
Schizoo
Schizoo Sep. 2 at 1:20 PM
$PLRZ great news today..
0 · Reply
Schizoo
Schizoo Sep. 1 at 8:25 PM
$PLRZ held up really strokg on a red day.. :)
0 · Reply
Schizoo
Schizoo Sep. 1 at 7:00 PM
$PLRZ yuup! Balls n patience.. 18$ is the next resistance and after that we will probably run..
0 · Reply
patrick1956
patrick1956 Sep. 1 at 6:34 PM
$PLRZ ...this is a coordinated attack by the hedge fund...they borrowed 150k shares to short this down..they dark pool 125k just today...don't get fool in this plan..
1 · Reply
Schizoo
Schizoo Sep. 1 at 2:13 PM
$PLRZ bullish upptrend.. resistance at 18ish....
2 · Reply